Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Ascendis Pharma AS ASND

Healthcare Biotechnology
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic... see more

Current News (NDAQ:ASND)

Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire 3 days ago

Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)

GlobeNewswire 4 days ago

Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire 7 days ago

Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia

GlobeNewswire November 25, 2025

Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics

GlobeNewswire November 17, 2025

Ascendis Pharma Reports Third Quarter 2025 Financial Results

GlobeNewswire November 12, 2025

New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism

GlobeNewswire November 7, 2025

Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025

GlobeNewswire November 5, 2025

3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025

GlobeNewswire November 3, 2025
View More News ››

Opinion & Analysis (NDAQ:ASND)

VIDEO: Ascendant Resources: Production Numbers Of Q3 2017

Commodity-TV October 19, 2017
View More Opinion ››

Bullboard Posts (NDAQ:ASND)

Be the first to post on this bullboard.

Kobrea Exploration Corp.

Kobrea Exploration Corp.

Kobrea Exploration Corp. engages in the acquisition, exploration, and evaluation of mineral properties in Canada. It holds a ...
View More »

Podcasts